Savolitinib Plus Tagrisso Added About Five Months of Median Survival Over Chemo in MET-Driven Lung Cancer
AstraZeneca and HUTCHMED's savolitinib plus Tagrisso combo extended median survival to 17.8 months vs. 12.9 months with chemo in MET-driven lung cancer, per SAFFRON trial results. The combo reduced death risk by 32%. Side effects were comparable, but the combo had different profile. The combo is not yet FDA-approved.
How this was made
The 30-second read
Why it matters
The data could accelerate FDA review and influence market expectations for both companies' oncology pipelines.
Market read
First disclosure of pivotal trial outcomes; likely to move both stocks and the broader MET‑targeted oncology space.
What to watch
The trial was open‑label and not compared to newer EGFR inhibitors; competitive landscape could limit upside.
Background
The SAFFRON phase III trial results were published in NEJM and presented at ESMO, providing the first comprehensive efficacy and safety data for the savolitinib‑Tagrisso combo in MET‑driven EGFR‑mutated lung cancer.
Ticker impact
AstraZeneca co‑developed savolitinib plus Tagrisso; the new NEJM trial data show a median overall survival of 17.8 months versus 12.9 months with chemotherapy, the first public disclosure of these results.
likely upward pressure as investors price in higher chance of US approval and future sales.
First‑time release of statistically significant survival benefit; market typically reacts favorably to pivotal oncology data.
Market effects
Oncology biotech sector may see increased investor interest in MET‑targeted therapies.
US and Hong Kong biotech markets could experience modest gains as the data support upcoming FDA decisions.
Global pharma investors may reassess pipelines involving MET inhibition.
Counterpoint
If regulatory scrutiny intensifies or safety concerns emerge, the positive data may be priced out quickly.
Key entities
- CompanyAstraZeneca
Co‑developer and marketer of Tagrisso; partner in the savolitinib combination.
- CompanyHUTCHMED
Co‑developer of savolitinib; holds Chinese approval for the combo.
